Physician profile
Michael C Staley
NPI 1912903659
$3,981.41
in general payments reported to CMS, 2019-2025
30 companies · $80.51 in 2025
The $80.51 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $562 · 2020: $1,679 · 2021: $1,527 · 2022: $49.67 · 2023: $60.87 · 2024: $22.19 · 2025: $80.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $163.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $861.47 | 2019-2021 | |
| Neotract INC. | $612.57 | 2019-2020 | |
| Astellas Pharma US INC | $398.38 | 2019-2021 | |
| Teleflex LLC | $357.35 | 2021-2022 | |
| Abbvie INC. | $269.42 | 2019-2025 | Botox |
| Antares Pharma, INC. | $229.18 | 2019-2021 | |
| Rochester Medical Corporation | $217.87 | 2020-2021 | |
| Cipla USA INC. | $177.25 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $164.51 | 2019-2021 | |
| Janssen Biotech, INC. | $129.26 | 2019-2021 | |
| Pfizer INC. | $75.20 | 2019-2021 | |
| Clarus Therapeutics INC. | $71.60 | 2021 | |
| Blue Earth Diagnostics | $58.34 | 2019-2021 | |
| Myovant Sciences INC. | $57.18 | 2021 | |
| Merck Sharp & Dohme LLC | $41.24 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $40.97 | 2020-2021 | |
| Baudax Bio INC. | $26.28 | 2020 | |
| Axonics, INC. | $22.19 | 2024 | Bulkamid, Axonics |
| Dendreon Pharmaceuticals LLC | $19.19 | 2019 | |
| Amgen INC. | $18.86 | 2019 | |
| Boston Scientific Corporation | $17.38 | 2019 | |
| Metuchen Pharmaceuticals | $16.18 | 2020 | |
| Acerus Pharmaceuticals Corporation | $14.39 | 2021 | |
| Travere Therapeutics, INC. | $13.94 | 2021 | |
| Convatec INC. | $13.21 | 2021 | |
| Melinta Therapeutics, LLC | $13.17 | 2019 | |
| Allergan, INC. | $12.37 | 2021 | |
| C. R. Bard, INC. & Subsidiaries | $11.88 | 2019 | |
| 180 Medical, INC. | $11.15 | 2020 | |
| Ambu INC. | $9.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Staley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.